Upregulator of cell proliferation predicts poor prognosis in hepatocellular carcinoma and contributes to hepatocarcinogenesis by downregulating FOXO3a

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Xie, Chan ^a,b   Song, Li bing ^b   Wu, Jue heng ^c   Li, Jun ^c   Yun, Jing ping ^d   Lai, Jia ming ^e   Xie, Dong ying ^a   Lin, Bing liang ^a   Yuan, Yun fei ^d   Li, Mengfeng ^b   Gao, Zhi liang ^a,b  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^e THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MESSENGER RNA; PROTEIN KINASE B; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FKHRL1; TUMOR MARKER; UNCLASSIFIED DRUG; UPREGULATOR OF CELL PROLIFERATION PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; URGCP GENE; WESTERN BLOTTING;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; DOWN-REGULATION; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MICE; MICE, SCID; NEOPLASM PROTEINS; PROGNOSIS; PROTEIN KINASE INHIBITORS; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84864004532     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040607     Document Type: Article

References (42)

1. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
2. Llovet JM, Burroughs A, Bruix J, (2003) Hepatocellular carcinoma. Lancet 362: 1907-1917.
3. Chen CJ, Yang HI, Su J, Jen CL, You SL, et al. (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295: 65-73.
4. Aravalli RN, Steer CJ, Cressman EN, (2008) Molecular mechanisms of hepatocellular carcinoma. Hepatology 48: 2047-2063.
5. Sasaki Y, Yamada T, Tanaka H, Ohigashi H, Eguchi H, et al. (2006) Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B- or hepatitis C-related hepatocellular carcinoma. Ann Surg 244: 771-780.
6. Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, et al. (1995) Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg 221: 291-298.
7. Ercolani G, Grazi GL, Ravaioli M, Del Gaudio M, Gardini A, et al. (2003) Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg 237: 536-543.
8. Kinugasa H, Nouso K, Takeuchi Y, Yasunaka T, Onishi H, et al. (2011) Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma. J Gastroenterol doi:10.1007/s00535-011-0492-9.
9. Qiu J, Huang P, Liu Q, Hong J, Li B, et al. (2011) Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. Journal of Translational Medicine 9: 166-176.
10. El-Serag HB, (2004) Hepatocellular carcinoma: recent trends in the United States.Gastroenterology 127 (Suppl): S27-34.
11. Sherman M, (2008) Recurrence of hepatocellular carcinoma. N Engl J Med 359: 2045-2047.
12. Giuseppe Manghisi, Silvana Elba, Ascanio Mossa, Antonio Giorgio, Vincenza Aloisio, et al. (1998) A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28: 751-755.
13. Kudo M, Chung H, Osaki Y, (2003) Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 38: 207-215.
14. Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, et al. (2010) Selecting an Optimal Staging System for Hepatocellular Carcinoma - Comparison of 5 Currently Used Prognostic Models. Cancer 15: 3006-3014.
15. Kaseb AO, Hassan MM, Lin E, Xiao L, Kumar V, et al. (2011) V-CLIP: Integrating Plasma Vascular Endothelial Growth Factor Into a New Scoring System to Stratify Patients With Advanced Hepatocellular Carcinoma for Clinical Trials. Cancer 1: 2478-2489.
16. Wang JH, Changchien CS, Hu TH, Lee CM, Kee KM, et al. (2008) The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma: survival analysis of 3,892 patients. Eur J Cance 44: 1000-1006.
17. Koike K, Moriya K, Iino S, Yotsuyanagi H, Endo Y, et al. (1994) High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. Hepatology 19: 810-819.
18. Tufan NL, Lian Z, Liu J, Pan J, Arbuthnot P, et al. (2002) Hepatitis Bx antigen stimulates expression of a novel cellular gene, URG4, that promotes hepatocellular growth and survival. Neoplasia 4: 355-368.
19. Song J, Xie H, Lian Z, Yang G, Du R, et al. (2006) Enhanced cell survival of gastric cancer cells by a novel gene URG4. Neoplasia 12: 995-1002.
20. Huang J, Zhu B, Lu L, Lian Z, Wang Y, et al. (2009) The expression of novel gene URG4 in osteosarcoma: correlation with patients' prognosis. Pathology 41: 149-154.
21. Peng SY, Chou SP, Hsu HC, (1998) Association of downregulation of cyclin D1 and of overexpression of cyclin E with p53 mutation, high tumor grade and poor prognosis in hepatocellular carcinoma. J Hepato 29: 281-289.
22. Ito Y, Matsuura N, Sakon M, Miyoshi E, Noda K, et al. (1999) Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology 30: 90-99.
23. Li J, Zhang N, Song LB, Liao WT, Jiang LL, et al. (2008) Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival. Clin Cancer Res 14: 3319-3326.
24. Huang H, Tindall DJ, (2007) FoxO transcription factors. J Cell Sci 120: 2479-2487.
25. Wang WL, London WT, Lega L, Feitelson MA, (1991) HBxAg in liver from carrier patients with chronic hepatitis and cirrhosis. Hepatology 14: 29-37.
26. Benn J, Schneider RJ, (1995) Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls. Proc Natl Acad Sci 92: 11215-11219.
27. Lian Z, Liu J, Li L, Li X, Clayton M, et al. (2006) Enhanced cell survival of Hep3B cells by the hepatitis B x antigen effector, URG11, is associated with upregulation of beta-catenin. Hepatology 43: 415-424.
28. Du R, Huang C, Bi Q, Zhai Y, Xia L, et al. (2010) URG11 mediates hypoxia-induced epithelial-to-mesenchymal transition by modulation of E-cadherin and β-catenin. Biochem Biophys Res Commun 391: 135-141.
29. Fan R, Li X, Du W, Zou X, Du R, et al. (2011) Adenoviral-mediated RNA interference targeting URG11 inhibits growth of human hepatocellular carcinoma. Int J Cancer 128: 2980-2993.
30. Pan J, Lian Z, Wallett S, Feitelson MA, (2007) The hepatitis B x antigen effector, URG7, blocks tumour necrosis factor alpha-mediated apoptosis by activation of phosphoinositol 3-kinase and beta-catenin. J Gen Viro 88: 3275-3285.
31. Lu M, Ma J, Xue W, Cheng C, Wang Y, et al. (2009) The expression and prognosis of FOXO3a and Skp2 in human hepatocellular carcinoma. Pathol Oncol Res 15: 679-687.
32. Kim BC, (2008) FoxO3a mediates transforming growth factor-beta1-induced apoptosis in FaO rat hepatoma cells. BMB Rep 41: 728-732.
33. Brognard J, Clark AS, Ni Y, Dennis PA, (2001) Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Re 61: 3986-3997.
34. Andre F, Nahta R, Conforti R, Boulet T, Aziz M, et al. (2008) Expression patterns and predictive value of phosphorylated Akt in early-stage breast cancer. Ann Onc 19: 315-320.
35. Sonoda Y, Ozawa T, Aldape KD, Deen DF, Berger MS, et al. (2001) Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Re 61: 6674-6678.
36. Y Nie, (2011) Foxo3a regulates hepatitis b virus replication by the activation of HBV enhancer 1 function. J Hepatol 54 (Suppl): 441A.
37. Krasilnikov M, Ivanov VN, Dong J, Ronai Z, (2003) ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis. Oncogene 22: 4092-4101.
38. Saxena NK, Sharma D, Ding X, Lin S, Marra F, et al. (2007) Concomitant activation of the JAK/STAT, PI3K/Akt, and ERK signaling is involved in leptin-ediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 67: 2497-2507.
39. Li W, Tan D, Zhang Z, Liang JJ, Brown RE, (2008) Activation of Akt-mTOR-p70S6K pathway in angiogenesis in hepatocellular carcinoma. Oncol Rep 20: 713-719.
40. Chen JS, Wang Q, Fu XH, Huang XH, Chen XL, et al. (2009) Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol Res 39: 177-186.
41. Nakanishi K, Sakamoto M, Yamasaki S, Todo S, Hirohashi S, (2005) Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular arcinoma. Cancer 103: 307-312.
42. Llovet JM, Bruix J, (2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48 (Suppl): 20-37.